Autopsy report · NCT04718376

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer

“The sponsor has adjusted its R\&D strategy.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 4 months before it stopped.
• 56 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Sponsor type

Industry

Conditions

Platinum-resistant Ovarian Cancer

Interventions

Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)

Participants

56

Sites

7

Countries

China

Trials that died the same way

• A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC
  “The sponsor's R\&D strategy is adjusted.” (98% match in meaning)
• A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
  “Sponsor's R\&D strategy adjusted.” (96% match in meaning)
• A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
  “Sponsor R \& D Strategy Adjustment” (89% match in meaning)
• Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.
  “The Sponsor changed R\&D strategy and priority.” (89% match in meaning)
• Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
  “sponsor strategy change” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.